[1] |
HERRINGTON W, LACEY B, SHERLIKER P, et al. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease[J]. Circ Res,2016,118(4):535-546. doi: 10.1161/CIRCRESAHA.115.307611 |
[2] |
NAKAMURA T, UEMATSU M, YOSHIZAKI T, et al. Improvement of endothelial dysfunction is mediated through reduction of remnant lipoprotein after statin therapy in patients with coronary artery disease[J]. J Cardiol,2020,75(3):270-274. doi: 10.1016/j.jjcc.2019.08.006 |
[3] |
KARR S. Epidemiology and management of hyperlipidemia[J]. Am J Manag Care,2017,23(9 suppl):S139-S148. |
[4] |
EMINI VESELI B, PERROTTA P, DE MEYER G R A, et al. Animal models of atherosclerosis[J]. Eur J Pharmacol,2017,816:3-13. doi: 10.1016/j.ejphar.2017.05.010 |
[5] |
OPOKU S, GAN Y, FU W N, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and Prevention Project (CNSSPP)[J]. BMC Public Health,2019,19(1):1500. doi: 10.1186/s12889-019-7827-5 |
[6] |
ROBINSON J G. Lipid management beyond the guidelines[J]. Prog Cardiovasc Dis,2019,62(5):384-389. doi: 10.1016/j.pcad.2019.10.004 |
[7] |
WONG N D, ROSENBLIT P D, GREENFIELD R S. Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond[J]. Cardiovasc Diagn Ther,2017,7(suppl 1):S11-S20. |
[8] |
MEYRELLES S S, PEOTTA V A, PEREIRA T M, et al. Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging[J]. Lipids Health Dis,2011,10:211. doi: 10.1186/1476-511X-10-211 |
[9] |
鲍和, 张昌龙, 苏娅萍, 等. 高脂饮食诱导建立小鼠高脂血症模型[J]. 西北药学杂志, 2019, 34(1):47-51. doi: 10.3969/j.issn.1004-2407.2019.01.012 |
[10] |
郝维佳, 杨秋实, 李静宜, 等. 高脂饲料中添加丙硫氧嘧啶对大鼠血脂、体质量及体脂的影响[J]. 首都医科大学学报, 2018, 39(3):385-392. doi: 10.3969/j.issn.1006-7795.2018.03.014 |
[11] |
戴贻权, 颜晓晓, 刘晓如, 等. 小鼠动脉粥样硬化模型的建立[J]. 中华实验外科杂志, 2020, 37(1):172-175. doi: 10.3760/cma.j.issn.1001-9030.2020.01.050 |
[12] |
MÄRZ W, KLEBER M E, SCHARNAGL H, et al. HDL cholesterol: reappraisal of its clinical relevance[J]. Clin Res Cardiol,2017,106(9):663-675. doi: 10.1007/s00392-017-1106-1 |
[13] |
RIGGS K A, ROHATGI A. HDL and reverse cholesterol transport biomarkers[J]. Methodist Debakey Cardiovasc J,2019,15(1):39-46. |
[14] |
DORAN B, GUO Y, XU J F, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality[J]. Circulation,2014,130(7):546-553. doi: 10.1161/CIRCULATIONAHA.114.010001 |
[15] |
LANGSTED A, NORDESTGAARD B G. Nonfasting versus fasting lipid profile for cardiovascular risk prediction[J]. Pathology,2019,51(2):131-141. doi: 10.1016/j.pathol.2018.09.062 |
[16] |
NORDESTGAARD B G. A test in context: lipid profile, fasting versus nonfasting[J]. J Am Coll Cardiol,2017,70(13):1637-1646. doi: 10.1016/j.jacc.2017.08.006 |
[17] |
TOUMA Z, GLADMAN D D, IBAÑEZ D, et al. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients[J]. Rheumatology (Oxford),2012,51(3):528-534. doi: 10.1093/rheumatology/ker339 |
[18] |
LI Y L, HE J X, ZENG X L, et al. Non-fasting lipids detection and their significance in pregnant women[J]. Lipids Health Dis,2019,18(1):96. doi: 10.1186/s12944-019-1038-z |